BridgeBio's BBP-418 Receives FDA Priority Review for LGMD2I/R9
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: Newsfilter
- FDA Priority Review: BridgeBio's BBP-418 has been accepted for FDA Priority Review with a target action date of November 27, 2026, and if approved, it will be the first treatment option for LGMD2I/R9 patients, addressing a critical unmet need in this community.
- Clinical Trial Success: In the Phase 3 FORTIFY trial, BBP-418 demonstrated significant efficacy across all primary and secondary endpoints, with treated individuals improving on key measures while placebo recipients declined, indicating the drug's potential impact on disease progression.
- Significant Market Potential: Approximately 7,000 individuals in the U.S. and Europe currently live with LGMD2I/R9, and the successful launch of BBP-418 could provide new hope for these patients, potentially becoming the first approved therapy for any form of LGMD, which holds substantial market significance.
- Future Development Plans: BridgeBio intends to initiate clinical studies of BBP-418 for individuals under 12 years of age in the near future and is actively engaging with regulatory agencies to identify an expedited approval pathway in Europe, further expanding its market reach.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 68.450
Low
85.00
Averages
98.50
High
157.00
Current: 68.450
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BridgeBio Pharma's BBP-418 Receives FDA Priority Review
- FDA Priority Review: BridgeBio Pharma's BBP-418 oral therapy has received priority review from the FDA for a rare muscle disorder, limb-girdle muscular dystrophy, marking a significant advancement in the biotech sector.
- Target Action Date: The FDA has set November 27, 2026, as the target action date for the new drug application, which will significantly impact the company's future market strategy and cash flow.
- Market Potential: If approved, BBP-418 will be the first and only therapy for LGMD2I/R9 in the U.S., expected to fill a market gap and provide substantial revenue growth opportunities for the company.
- Regulatory Dynamics: Although the FDA has not indicated plans for an advisory committee meeting to discuss the NDA, the priority review decision reflects the agency's recognition of the therapy's potential value, potentially accelerating its path to market.
See More
BridgeBio's BBP-418 Receives FDA Priority Review for LGMD2I/R9
- FDA Priority Review: BridgeBio's BBP-418 has been accepted for FDA Priority Review with a target action date of November 27, 2026, and if approved, it will be the first treatment option for LGMD2I/R9 patients, addressing a critical unmet need in this community.
- Clinical Trial Success: In the Phase 3 FORTIFY trial, BBP-418 demonstrated significant efficacy across all primary and secondary endpoints, with treated individuals improving on key measures while placebo recipients declined, indicating the drug's potential impact on disease progression.
- Significant Market Potential: Approximately 7,000 individuals in the U.S. and Europe currently live with LGMD2I/R9, and the successful launch of BBP-418 could provide new hope for these patients, potentially becoming the first approved therapy for any form of LGMD, which holds substantial market significance.
- Future Development Plans: BridgeBio intends to initiate clinical studies of BBP-418 for individuals under 12 years of age in the near future and is actively engaging with regulatory agencies to identify an expedited approval pathway in Europe, further expanding its market reach.
See More
BridgeBio Pharma Shares Drop After Downgrade by Raymond James
- Downgrade Impact: Raymond James downgraded BridgeBio Pharma (BBIO) from Outperform to Market Perform, primarily due to the anticipated impact of Pfizer's heart drug Vyndamax losing exclusivity, suggesting that BBIO's stock is unlikely to sustain upward momentum amid growing market concerns.
- Increased Competitive Risks: Analyst Martin Auster indicated that with Vyndamax's loss of exclusivity, Attruby's market share could be jeopardized, predicting that new patient starts will become challenging beyond 2031, despite BBIO's efforts to establish a differentiated clinical profile among certain prescribers.
- Market Pressure Expectations: Auster expects that as Vyndamax's exclusivity nears its end, the ATTR-CM therapy market will increasingly rely on formulary-driven dynamics, which may exert greater pressure on TTR stabilizers, potentially undermining BBIO's revenue diversification strategy.
- Price Target Removal: The analyst has removed the $89 price target for BBIO, reflecting a cautious outlook on the company's growth potential, indicating that in a payer-driven market environment, BBIO will need to exert significant efforts to maintain its market position.
See More
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
- Cost Warning for Cardiovascular Disease: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment approaches for cardiac patients, potentially leading to significant industry transformation.
- Growth of AI Cardiology Market: The global AI cardiology market is valued at $2.78 billion this year and is projected to exceed $14 billion by 2034, driving health systems to accelerate the deployment of machine learning tools to address diagnostic backlogs, thereby enhancing medical efficiency and patient satisfaction.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform, VMS+™ 4.0, at the AEPC annual meeting in Italy, which can convert standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI while significantly reducing equipment costs and wait times.
- International Collaborations and Market Expansion: VentriPoint has established relationships with multiple international partners, including Lishman Global, which is applying for regulatory approval in China, and collaborations in Costa Rica and Indigenous communities in Canada, demonstrating its growth potential and strategic positioning in the global cardiac diagnostics market.
See More
BridgeBio's Encaleret Shows Promising Phase 3 Results for ADH1
- Successful Clinical Trial: At the 2026 European Congress of Endocrinology, BridgeBio presented Phase 3 CALIBRATE trial results, showing that 76% of participants on encaleret achieved target serum and urine calcium levels at Week 24, a significant increase from 4% on conventional therapy, highlighting the drug's potential in treating ADH1.
- Market Opportunity: BridgeBio anticipates a U.S. launch of encaleret in early 2027, which, if approved, would be the first therapy specifically indicated for ADH1, addressing the urgent needs of nearly 2,000 diagnosed patients in the U.S. and indicating a substantial market opportunity.
- Favorable Safety Profile: No discontinuations were reported in the encaleret group, and the rate of serious adverse events was similar to the control group, indicating a good safety and tolerability profile that supports future market adoption.
- Future Research Plans: BridgeBio plans to initiate the RECLAIM-HP Phase 3 clinical study in Summer 2026, further exploring encaleret's applications in chronic hypoparathyroidism, thereby expanding its indications and enhancing the company's competitiveness in the genetic disease sector.
See More
BridgeBio Pharma's BBP-418 Receives FDA Priority Review
- FDA Priority Review: BridgeBio Pharma's BBP-418 oral therapy has received priority review from the FDA for a rare muscle disorder, limb-girdle muscular dystrophy, marking a significant advancement in the biotech sector.
- Target Action Date: The FDA has set November 27, 2026, as the target action date for the new drug application, which will significantly impact the company's future market strategy and cash flow.
- Market Potential: If approved, BBP-418 will be the first and only therapy for LGMD2I/R9 in the U.S., expected to fill a market gap and provide substantial revenue growth opportunities for the company.
- Regulatory Dynamics: Although the FDA has not indicated plans for an advisory committee meeting to discuss the NDA, the priority review decision reflects the agency's recognition of the therapy's potential value, potentially accelerating its path to market.
See More
BridgeBio's BBP-418 Receives FDA Priority Review for LGMD2I/R9
- FDA Priority Review: BridgeBio's BBP-418 has been accepted for FDA Priority Review with a target action date of November 27, 2026, and if approved, it will be the first treatment option for LGMD2I/R9 patients, addressing a critical unmet need in this community.
- Clinical Trial Success: In the Phase 3 FORTIFY trial, BBP-418 demonstrated significant efficacy across all primary and secondary endpoints, with treated individuals improving on key measures while placebo recipients declined, indicating the drug's potential impact on disease progression.
- Significant Market Potential: Approximately 7,000 individuals in the U.S. and Europe currently live with LGMD2I/R9, and the successful launch of BBP-418 could provide new hope for these patients, potentially becoming the first approved therapy for any form of LGMD, which holds substantial market significance.
- Future Development Plans: BridgeBio intends to initiate clinical studies of BBP-418 for individuals under 12 years of age in the near future and is actively engaging with regulatory agencies to identify an expedited approval pathway in Europe, further expanding its market reach.
See More
BridgeBio Pharma Shares Drop After Downgrade by Raymond James
- Downgrade Impact: Raymond James downgraded BridgeBio Pharma (BBIO) from Outperform to Market Perform, primarily due to the anticipated impact of Pfizer's heart drug Vyndamax losing exclusivity, suggesting that BBIO's stock is unlikely to sustain upward momentum amid growing market concerns.
- Increased Competitive Risks: Analyst Martin Auster indicated that with Vyndamax's loss of exclusivity, Attruby's market share could be jeopardized, predicting that new patient starts will become challenging beyond 2031, despite BBIO's efforts to establish a differentiated clinical profile among certain prescribers.
- Market Pressure Expectations: Auster expects that as Vyndamax's exclusivity nears its end, the ATTR-CM therapy market will increasingly rely on formulary-driven dynamics, which may exert greater pressure on TTR stabilizers, potentially undermining BBIO's revenue diversification strategy.
- Price Target Removal: The analyst has removed the $89 price target for BBIO, reflecting a cautious outlook on the company's growth potential, indicating that in a payer-driven market environment, BBIO will need to exert significant efforts to maintain its market position.
See More
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
- Cost Warning for Cardiovascular Disease: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment approaches for cardiac patients, potentially leading to significant industry transformation.
- Growth of AI Cardiology Market: The global AI cardiology market is valued at $2.78 billion this year and is projected to exceed $14 billion by 2034, driving health systems to accelerate the deployment of machine learning tools to address diagnostic backlogs, thereby enhancing medical efficiency and patient satisfaction.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform, VMS+™ 4.0, at the AEPC annual meeting in Italy, which can convert standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI while significantly reducing equipment costs and wait times.
- International Collaborations and Market Expansion: VentriPoint has established relationships with multiple international partners, including Lishman Global, which is applying for regulatory approval in China, and collaborations in Costa Rica and Indigenous communities in Canada, demonstrating its growth potential and strategic positioning in the global cardiac diagnostics market.
See More
BridgeBio's Encaleret Shows Promising Phase 3 Results for ADH1
- Successful Clinical Trial: At the 2026 European Congress of Endocrinology, BridgeBio presented Phase 3 CALIBRATE trial results, showing that 76% of participants on encaleret achieved target serum and urine calcium levels at Week 24, a significant increase from 4% on conventional therapy, highlighting the drug's potential in treating ADH1.
- Market Opportunity: BridgeBio anticipates a U.S. launch of encaleret in early 2027, which, if approved, would be the first therapy specifically indicated for ADH1, addressing the urgent needs of nearly 2,000 diagnosed patients in the U.S. and indicating a substantial market opportunity.
- Favorable Safety Profile: No discontinuations were reported in the encaleret group, and the rate of serious adverse events was similar to the control group, indicating a good safety and tolerability profile that supports future market adoption.
- Future Research Plans: BridgeBio plans to initiate the RECLAIM-HP Phase 3 clinical study in Summer 2026, further exploring encaleret's applications in chronic hypoparathyroidism, thereby expanding its indications and enhancing the company's competitiveness in the genetic disease sector.
See More
